ResistanceBio
Operating Status: Closed
Resistance Bio aids in combating treatment-resistant cancer through pre-clinical discovery and solutions.
Resistance Bio aids in combating treatment-resistant cancer through pre-clinical discovery and solutions.
Founded with a mission to combat treatment-resistant cancer, ResistanceBio focuses on pre-clinical discovery and solutions to overcome clinical treatment resistance. The company leverages a unique platform that generates real resistance data, aiming to provide innovative solutions for patients who do not respond to conventional cancer treatments. By addressing a critical gap in cancer therapy, ResistanceBio targets a specialized market of healthcare providers and researchers dedicated to improving cancer treatment outcomes.
ResistanceBio has garnered attention for its pioneering approach and has attracted notable investors and experts in the oncology field. The company's key achievements include developing a robust platform that offers actionable insights into drug resistance, potentially transforming the landscape of cancer treatment. Through its innovative solutions, ResistanceBio has made a significant impact on the fight against treatment-resistant cancer, offering hope to patients and advancing the capabilities of modern oncology.
Companies similar to ResistanceBio include Serinus Biosciences, Viosera Therapeutics, Alixia and First Ascent Biomedical.
ResistanceBio was founded in 2016.
ResistanceBio's headquarters is located in San Carlos, CA, US.
ResistanceBio's most recent funding round was for $12.8M (USD) in January 2024.
As of Jan 29, 2024, ResistanceBio has disclosed funding of $24.8M (USD). Undisclosed round amounts are excluded.
First Ascent Biomedical
firstascentbio.com
